Viral capture of antibody tails blocks multiple routes for eliminating infected cells
In older-donor tissue, human cytomegalovirus may block several immune killing routes by capturing antibody tails. Preventing that capture should restore infected-cell elimination and reduce viable pathogen burden at unchanged antibody dose and local concentration; better delivery alone should fail.
Omega Point 1.2
Stage of verification
- Hypothesis published2026-09-21
- Experiments support key linksAssessed at 6 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Biological function
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.
Receptor or channel
HCMV Fc-binding proteins
Viral proteins that bind antibody Fc and obstruct its engagement with host Fc receptors
Where this hypothesis actsInfected targets in older-donor tissue with adequate antibody occupancy but impaired Fc-dependent clearance
Hypotheses on this target 1
Lower level
Higher level
Blockade1
Agonism
Desensitisation
Function restoration
Function preservation
What is proposed
Blockade
Prevent viral proteins from capturing antibody Fc
With whatAntibody or binding reagent
HowUse Fc variants with reduced viral-receptor binding while matching antibody dose, Fab specificity, neutralization, host Fc-receptor binding and tissue occupancy
Possible result
Expected restoration of infected-target elimination and viable-burden decline without increasing antibody dose
From the recordHCMV Fc-binding proteins and Fc variants with reduced viral-receptor binding provide experimental handles.
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
Antibodies can reach an infection and still fail to help the body remove infected cells. The unexpected move is that several backup routes for removing those cells may share the same vulnerable point: the antibody tail that calls other immune cells into action. Viral capture of that tail could disable the backups together; this is a proposal generated by the pipeline, not a measured result in older human tissue.
- Supplied antibodies reach infected tissue and attach to their targets.
- Viral proteins capture the antibody tails that would otherwise engage immune-cell receptors.
- Separate routes that could each remove infected cells become jointly blocked because both require accessible antibody tails.
- Additional antibody delivery leaves this shared block in place, so infected cells persist despite blood activity that appears protective.
- Selective prevention of tail capture lets immune cells engage the antibodies again and is predicted to restore infected-cell removal and reduce the amount of viable virus.
Two backup crews can clear the same obstruction, but both need a key from the same locked cabinet. Sending more supplies does not release the key.
Where the picture breaks: Antibody capture is a molecular interaction, not an absolute lock. The picture does not establish how completely capture blocks either route, whether both routes can independently clear the infection, or whether increasing antibody supply could overcome capture.
- Master questionstep 01 of 04
Lasting recovery from age-related immune dysfunction would restore both broad, immediate defenses and defenses tailored to particular threats to healthy young-adult ranges. It would also preserve memory of past threats, restraint against attacking the body's own tissues, and control of infections that remain in the body without being continuously active.
Rests on: The goal defines recovery as restored function together with preservation of existing protection.
AssumptionHealthy young-adult ranges are taken as the reference for recovery. The supplied material does not specify the functions, reference ranges, or duration required to meet that goal.
- Goal pillarstep 02 of 04
Immune protection must resist failures between recognizing a threat, displaying pieces of it to immune cells, and carrying out its removal.
Rests on: The master question requires restored immune function, but does not identify these transfers between tasks as a separate condition for recovery.
AssumptionThe pillar takes resistance to failures between these tasks as a necessary part of recovery. Its title supplies no further argument for that choice.
- Gap questionstep 03 of 04
Supplied antibodies matched to a threat might fail to compensate for slow immune responses even when blood measurements indicate protection. Rescue by improving antibody movement into the affected tissue, without increasing dose, would challenge the sufficiency of those blood measurements.
Rests on: The preceding pillar names failures between immune tasks, but supplies no connection from those failures to antibody transport or to a mismatch between blood activity and tissue protection.
LeapThe missing bridge is evidence or an explicit rationale linking delayed immune action to inadequate local antibody transport despite protective blood activity. The screened sources do not establish that bridge.
- Hypothesisstep 04 of 04
Human cytomegalovirus, a virus abbreviated HCMV, is proposed to capture the Fc region, the antibody tail that engages immune-cell receptors. Even after antibodies reach infected tissue, that capture could disable several routes for removing infected cells at once. Preventing capture is predicted to restore removal without changing the antibody's target recognition or dose.S2S5
Rests on: The gap question supplies the contrast between blood activity and tissue failure; the endpoint proposes tail capture as an alternative to inadequate transport. Cell Reports (2025), S2, reports restored immune-cell activation and reduced viral spread with modified antibody tails in infected fibroblasts, connective-tissue cells, but does not establish simultaneous rescue of several removal routes in older human tissue. eLife (2021), S5, supports cooperative viral interference with antibody-receptor activation in cell experiments, but does not establish that more antibody or better delivery cannot overcome it.
Supported by literature
What is carried, and what is not. The screened literature supports antibody-tail capture and interference with immune-cell receptor activation; S2, Cell Reports (2025), also reports reduced viral spread after antibody-tail modification in infected fibroblasts, but that cell system does not establish clearance in older human tissue. No supplied source establishes the full sequence from adequate tissue delivery through simultaneous failure of multiple removal routes to rescue at unchanged dose and local antibody concentration.S2
Where the reasoning is carried by something unstated · 3
- Master question. Healthy young-adult ranges are taken as the reference for recovery. The supplied material does not specify the functions, reference ranges, or duration required to meet that goal.
- Goal pillar. The pillar takes resistance to failures between these tasks as a necessary part of recovery. Its title supplies no further argument for that choice.
- Gap question. The missing bridge is evidence or an explicit rationale linking delayed immune action to inadequate local antibody transport despite protective blood activity. The screened sources do not establish that bridge. Establish the missing link before relying on this step.
How a result here could mislead · 3
- Better clearance after changing an antibody tail could be credited to preventing viral capture even if the change instead improves binding to human immune-cell receptors, changes local antibody exposure, or changes viral reproduction. What closes it: The design requires independent matching of human receptor binding, local antibody concentration, target occupancy—the extent to which antibodies bind the intended targets—and pathogen reproduction. Reduced viral capture and restored receptor engagement must also be verified directly.
- Strong blood activity could be called protective even if the blood assay uses cells or virus preparations that are easier to block than the tissue infection. That would confuse the rival explanation of a mismatched assay with failure after antibodies have attached. What closes it: Neutralization, meaning prevention of new infection by antibodies, must be measured against the infection system relevant to the tissue experiment. Preventing tail capture must leave that activity unchanged, and any delivery intervention must be checked for changes in how readily the tissue cells admit infection.
- Persistent infection after adding a second removal route could be treated as evidence that viral capture disables both routes, although one route might never have been capable of clearing the defined target. A measurement of early infection blocking could also miss the rival's proposed later return of infectivity after antibodies detach. What closes it: Each removal route must first be shown sufficient on its own when capture is absent. Infected-cell elimination and the amount of viable virus must be assessed against a tissue-containment deadline fixed before the experiment, with testing for retained infectivity after antibody detachment. The supplied SPV_2 label has no operational definition, so its success criterion must also be specified in advance.
What would make this wrong. The proposal specifies two rejecting observations: preventing viral antibody-tail capture restores immune-cell receptor engagement but does not restore clearance, or correcting antibody transport alone fully restores clearance while capture remains unchanged. These observations require verified intervention effects and the stated matching of antibody activity, local exposure, and pathogen reproduction.
What it would change. If the proposal held, restoring blood antibody activity and tissue delivery would not by themselves establish restored protection: access to the antibody tail would be another condition to satisfy in this infection setting. Multiple backup routes would count as protection only after their shared vulnerability had been addressed. Even successful rescue in older-donor tissue would not establish durable recovery across the immune system in people, preservation of immune memory and restraint against self-attack, or control of other persistent infections.
Sources read · 6
A viral glycoprotein targets IgG+ memory B cells to mediate humoral immune evasion. · EMBO molecular medicine · 2026
“The interaction between gp34 1-179 and IgG was shown to block IgG-mediated activation of FcγRI, II, and III (Corrales-Aguilar et al, ).”
Does not settle: This text does not establish effects on infected target-cell elimination, antibody delivery or dose, blood-side neutralization, complement activity in HCMV, or restoration of any SPV_2 endpoint by restoring Fc accessibility at unchanged Fab specificity and dose.
Selective decoupling of IgG1 binding to viral Fc receptors restores antibody-mediated NK cell activation against HCMV. · Cell reports · 2025
“Here, we biochemically characterize two conserved vFcγRs, gp34 and gp68, and map their Fc binding sites. We then engineer Fc variants to retain binding to host Fc receptors CD16A and FcRn but exhibit markedly reduced gp34/gp68 interactions.”
Does not settle: The source establishes restored CD16A-associated immune-cell activation and reduced viral spread in HCMV-infected fibroblasts with engineered Fc domains. It does not establish protection in infected tissue in vivo, simultaneous blockade of multiple distinct cellular effector pathways, that added antibody or delivery cannot overcome the effect, or restoration of the stated SPV_2 endpoint at unchanged Fab specificity and dose.
Selective decoupling of IgG1 binding to viral Fc receptors restores antibody-mediated NK cell activation against HCMV. · bioRxiv : the preprint server for biology · 2025
“IgG1 antibodies targeting the gB fusogen with engineered Fc domains were not internalized by infected cells, mediated enhanced CD16A activation and limited viral spread in HCMV-infected fibroblasts more effectively than wild-type Fc.”
Does not settle: This source establishes improved CD16A activation and reduced viral spread in HCMV-infected fibroblasts with engineered Fc, but does not establish protection by blood-side neutralization, obstruction of multiple distinct cellular effector pathways, failure of increased antibody dose or delivery, or restoration in infected human tissue.
The human cytomegalovirus Fc receptor gp68 binds the Fc CH2-CH3 interface of immunoglobulin G. · Journal of virology · 2008
“Two human cytomegalovirus (HCMV)-encoded type I transmembrane receptors with Fcγ-binding properties (vFcγRs), gp34 and gp68, have been identified on the surface of HCMV-infected cells and are assumed to confer protection against IgG-mediated immunity.”
Does not settle: This source establishes gp68 Fc binding and notes gp34/gp68 on infected cells, but does not test obstruction of distinct cellular effector pathways, blood-side neutralization, antibody delivery or dose, restoration of Fc accessibility, or SPV_2.
Human cytomegalovirus antagonizes activation of Fcγ receptors by distinct and synergizing modes of IgG manipulation. · eLife · 2021
“In summary, we conclude that (i) gp34 is designed for internalization of IC while gp68 blocks FcγR binding to IC; (ii) gp34 and gp68 are able to antagonize FcγR activation individually when faced with titrated amounts of immune IgG, but non-immune IgG interferes with this inhibition; (iii) gp34 and gp68 show cooperativity in attenuating FcγR activation”
Does not settle: This source text supports cooperative interference with FcγR activation in infected-cell and reporter-cell experiments, but does not establish protection by blood-side neutralization, antibody delivery to infected tissue, failure across multiple cellular effector pathways, or that restoring Fc accessibility at unchanged Fab specificity and dose restores SPV_2.
Human cytomegalovirus Fcγ binding proteins gp34 and gp68 antagonize Fcγ receptors I, II and III. · PLoS pathogens · 2014
“Our approach identifies FcγRI, FcγRIIA and FcγRIII as principal targets of both HCMV gp34 and gp68”
Does not settle: This source does not establish passive-antibody delivery to infected tissue, blood-side neutralization, whether added antibody or improved delivery cannot overcome the effect, or restoration of SPV_2 at unchanged Fab specificity and dose.
The gap this hypothesis explains
Can restoring local transport make supplied antibodies clear their target during handoff delays without a higher dose?
Original wording · exactly as the pipeline generated it
Does target-matched passive antibody fail to bridge handoff delays despite protective blood activity, and can restoring local transport rescue clearance without increasing dose, falsifying circulating functional restoration as sufficient protection?
What this question is asking
The question asks whether supplied antibodies—proteins that recognize a particular target—can maintain protection while one protective process waits for another to take over. It asks whether antibodies matched to that target can fail during this delay even when their activity in blood appears protective, and whether restoring movement at the affected site can restore target removal at the same dose. The decisive comparison is target removal with and without restored local transport while the antibody dose stays unchanged. The question assumes that a handoff delay and a local transport problem can be identified, but the supplied material does not specify the processes involved, the target, the affected tissue, or what counts as protective blood activity. Its broader context is whether immune function in older people can return durably to healthy young-adult ranges while retaining recognition of previous threats, avoiding attacks on the body's own tissues, and keeping persistent infections controlled.
- Antibody
- A protein that recognizes a particular molecular feature of a target. Recognition, target removal, and protection are distinct outcomes in this question.
- Target-matched passive antibody
- An antibody supplied from outside the body and selected to recognize the target of interest. Passive describes the source of the antibody, rather than an immune response generated by the recipient.
- Handoff delay
- A proposed interval while protection passes between processes. The supplied material does not identify those processes or establish this as a defined biological event.
- Local transport
- Movement into, out of, or within the affected site. The question does not specify what moves, the route involved, or how restoration would be established.
- Protective blood activity
- Antibody function measured in blood and interpreted as sufficient for protection. The supplied material gives neither the measurement nor a criterion establishing that interpretation.
- Clearance
- Removal of a substance or biological target from a location. Removing an administered antibody, as addressed in S4, differs from removing the harmful target that antibody is intended to recognize.
- Dose
- The amount of a treatment administered. An unchanged dose is central to the question because the proposed rescue is attributed to transport restoration rather than to supplying more antibody.
- Circulating functional restoration
- Recovery of a measured function in blood. The question asks whether such recovery is enough to establish protection elsewhere in the body.
- Sufficient protection
- Protection that follows reliably when the stated conditions hold. A blood measurement associated with protection is not, by that association alone, a guarantee of protection.
- Tissue distribution and retention
- Distribution describes where a treatment goes in the body; retention describes its remaining at a location. These concern treatment location and do not by themselves measure successful target removal.
- Surface linings
- The moist tissue surfaces lining body passages, also called mucosal surfaces. S10 distinguishes antibody measurements there from measurements in blood.
- Influenza
- A viral infection used as the exposure setting in S10. That source concerns healthy volunteers, rather than the older population named in the broader question.
- Cynomolgus monkey
- A nonhuman primate species studied in S1. Its inclusion identifies the animal setting of that distribution finding.
- Antibody linked to a drug
- A treatment combining a target-recognizing antibody with a drug it carries. S1 reports where the intact combined product was found.
- Antibody-tracking data and mathematical models
- Tracking data record the behavior of marked antibodies; mathematical models combine such observations with representations of body processes. S4 uses these methods to estimate antibody removal in particular tissues.
- Age-related immune dysfunction
- Impaired immune function associated with aging. It encompasses multiple possible changes rather than one uniform state; the supplied gap detail does not specify which changes define the population.
- Innate and adaptive immunity
- Innate immunity comprises broadly responsive defenses, while adaptive immunity develops recognition of particular targets and can retain memory. Both appear in the broader objective, but the supplied question focuses on antibodies and transport.
- Protective immunological memory
- Retained immune recognition that helps defend against a previously encountered threat. Preserving it is a condition in the broader objective, not an outcome established by the supplied evidence.
- Self-tolerance
- Immune restraint toward the body's own tissues. The broader objective requires restored defenses to preserve this restraint.
- Latent infections
- Infections that persist in an inactive or relatively quiet state and can become active again. Maintaining their control is another condition in the broader objective.
Protective blood activity can coexist with a passive-antibody failure during handoff delays, and restoring local transport at an unchanged dose can rescue clearance and falsify circulating functional restoration as sufficient protection.
Supplied antibodies are target-recognizing proteins given from outside the body; a handoff delay would be a wait between protective processes, and local transport would be movement at the affected site. The question treats measurable blood protection, an identifiable delay, and a repairable movement problem as conditions that can be established together. If they were established, restoring target removal without adding more antibody could distinguish adequate blood activity from adequate protection at the site.
The supplied search results did not return work establishing this combined premise. S7 reports slow antibody distribution into tissue, and S10 cautions that blood antibody measurements may not represent antibodies at surface linings; neither establishes protective blood activity alongside failure during a defined handoff delay. No supplied source reports restoration of local transport rescuing target removal at an unchanged antibody dose. This does not establish that the premise is false.S7S10
The same question asked without the part nothing read establishes:
- During a defined delay between protective processes, does restoring local transport improve target removal by supplied antibodies at an unchanged dose?
- Does measured antibody activity in blood predict target removal and protection at the affected site?
- Failure followed by rescue at the same dose If blood activity met an independently established protective criterion but target removal failed during the delay, that blood criterion would not guarantee protection in the tested setting. If restoring local transport then restored target removal at the same dose, the result would support a local transport limitation; protection would still need to be distinguished from target removal alone.
- Supplied antibodies maintain protection If supplied antibodies maintained target removal and protection through the delay, the proposed failure would not occur in that setting. Local transport restoration would then not be shown necessary for bridging that delay, although this would not establish that blood measurements guarantee protection in every setting.
- Failure persists after transport restoration If target removal remained impaired after local transport was demonstrably restored at the same dose, repairing transport alone would not resolve the failure. The proposed transport explanation would therefore be insufficient, and the remaining cause would be unsettled.
The proposed chain runs from supplying an antibody, through its movement to the affected site, to removal of its target and protection during a delay. Slow antibody movement into tissue and differences between blood and surface-lining antibody measurements make location relevant, but do not establish that entire chain. [S7, S10] If blood activity appeared restored while local protection still failed, treating the blood measurement as sufficient could mistake an incomplete recovery for protection. Conversely, assuming transport explains the failure without evidence could misattribute a problem that the supplied sources have not located.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
Passive antibody reaches infected tissue, but nominally redundant cellular execution routes share an exploitable dependency: accessible antibody Fc. In an HCMV test case, viral Fc-binding proteins simultaneously obstruct Fc-receptor engagement by distinct effector pathways while blood-side neutralization remains protective. Adding antibody or improving delivery cannot reliably overcome this common cause of execution failure. Restoring Fc accessibility at unchanged Fab specificity and dose should restore SPV_2. The substrate is a pathogen-encoded molecular interception system on infected targets.
Where the idea comes from
The hypothesis borrows a result from another field. This is what it borrows, and from where.
Reliability engineering: a parallel redundant system with an explicit common-cause event. P_escape(T) = c(T) + [1-c(T)] q_N(T) q_P(T). T is the prespecified tissue-containment deadline; c(T) is the probability that viral Fc interception disables both execution routes through T; q_N(T) and q_P(T) are the conditional probabilities that NK-mediated elimination and phagocyte-mediated elimination, respectively, fail by T when interception is absent. Each route must first be shown independently sufficient for the defined target; conditional independence is a testable assumption. With interception present, redundancy has a failure floor c(T). The independent parallel-system product is described in [NIST's parallel or redundant model](https://www.itl.nist.gov/div898/handbook/apr/section1/apr183.htm); the common-cause mixture is the explicit biological extension.
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
In a factorial older-donor tissue experiment, improved antibody delivery alone fails despite adequate target occupancy. Selectively preventing viral Fc capture restores infected-target elimination and viable-burden decline at unchanged antibody dose, neutralization potency and local concentration. Increasing the number of Fc-dependent effector pathways provides little protection while Fc capture persists. This hypothesis is rejected if Fc-capture disruption restores receptor engagement but not clearance, or if transport correction alone fully rescues clearance with Fc capture unchanged.
States a measurable outcome; comparing rivals needs more conditions. The prediction specifies observable comparative outcomes and explicit rejection conditions. No rival prediction is supplied. A paper already fetched for this hypothesis bears on it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
HCMV Fc-binding proteins and Fc variants with reduced viral-receptor binding provide experimental handles. Neutralization, host Fc-receptor binding, tissue occupancy and pathogen replication must be independently matched. Whether multiple effector routes are jointly disabled in older human tissue remains to be established.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
In a factorial older-donor tissue experiment, improved antibody delivery alone fails despite adequate target occupancy. Selectively preventing viral Fc capture restores infected-target elimination and viable-burden decline at unchanged antibody dose, neutralization potency and local concentration. Increasing the number of Fc-dependent effector pathways provides little protection while Fc capture persists. This hypothesis is rejected if Fc-capture disruption restores receptor engagement but not clearance, or if transport correction alone fully rescues clearance with Fc capture unchanged.
- What would separate them
Some neutralizing antibodies preserve infectious particles and delay clearance predicts: At identical starting infectious burden, incubation conditions and antibody dose, antibody-exposed particles retain more recoverable infectivity after validated antibody removal than particles incubated without antibody. The advantage persists in cell-free incubation and with Fc-silent antibody, excluding Fc-mediated entry enhancement. In older-donor tissue, greater local delivery suppresses immediate infection yet increases subsequent rebound from surviving input particles. Absence of any antibody-dependent increase in infectious lifetime rejects this hypothesis even if ordinary neutralization is reversible.
- What would separate them
Blood antibody tests overstate protection when they do not match tissue infection predicts: At equal free antibody concentration, the original blood assay reports protection but a crossed assay using tissue-derived pathogen and matched primary target cells does not. After matching producer-cell history, target-cell phenotype and infection route, the unexplained blood–tissue discordance disappears. A purported transport rescue that acts through entry permissiveness also reduces infection in a no-antibody arm; selective antibody-delivery correction with target phenotype held constant provides no additional rescue. Persistent escape despite protective activity in the fully matched assay rejects this explanation.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
This hypothesis states no figure and cites no study, so there is nothing here to trace.
What it would take to refute it. 3 paper(s) already retrieved for this hypothesis carry its prediction’s terms. Reading them comes before running anything. Already retrieved: ISEV2025 Abstract Book.; ISEV2021 Abstract Book; ISEV2023 Abstract Book.
4 papers retrieved around this hypothesis
- ISEV2025 Abstract Book.PMID 41147645 · full_text · 3,430,026 characters stored
- ISEV2023 Abstract Bookeuropepmc:PMC:PMC10187017 · full_text · 1,743,218 characters stored
- The 7th Congress of Biophysicists of Russia - conference proceedings : Abstractseuropepmc:PMC:PMC10643713 · full_text · 1,008 characters stored
- ISEV2021 Abstract Bookeuropepmc:PMC:PMC8123387 · full_text · 1,401,847 characters stored
0 citation handles extracted; 1 Europe PMC search run; 4 records examined; 4 sources stored for enrichment, 4 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.